US20180161382A1 - Prebiotic compositions comprising one or more types of bacteriophage - Google Patents
Prebiotic compositions comprising one or more types of bacteriophage Download PDFInfo
- Publication number
- US20180161382A1 US20180161382A1 US15/837,730 US201715837730A US2018161382A1 US 20180161382 A1 US20180161382 A1 US 20180161382A1 US 201715837730 A US201715837730 A US 201715837730A US 2018161382 A1 US2018161382 A1 US 2018161382A1
- Authority
- US
- United States
- Prior art keywords
- bacteroides
- probiotic
- coli
- bacteriophage
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 241001515965 unidentified phage Species 0.000 title claims abstract description 75
- 235000013406 prebiotics Nutrition 0.000 title abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 44
- 230000012010 growth Effects 0.000 claims abstract description 22
- 210000002249 digestive system Anatomy 0.000 claims abstract description 6
- 239000006041 probiotic Substances 0.000 claims description 93
- 235000018291 probiotics Nutrition 0.000 claims description 93
- 230000000529 probiotic effect Effects 0.000 claims description 79
- 241000606124 Bacteroides fragilis Species 0.000 claims description 46
- 241000588724 Escherichia coli Species 0.000 claims description 38
- 241000606125 Bacteroides Species 0.000 claims description 37
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 27
- 241001608472 Bifidobacterium longum Species 0.000 claims description 25
- 241001522878 Escherichia coli B Species 0.000 claims description 23
- 244000057717 Streptococcus lactis Species 0.000 claims description 12
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 11
- 230000002101 lytic effect Effects 0.000 claims description 11
- 241000186660 Lactobacillus Species 0.000 claims description 10
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- 229920001202 Inulin Polymers 0.000 claims description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 9
- 229940029339 inulin Drugs 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 8
- 244000063299 Bacillus subtilis Species 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 240000001929 Lactobacillus brevis Species 0.000 claims description 6
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 6
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 6
- 241000606161 Chlamydia Species 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 4
- 241000194108 Bacillus licheniformis Species 0.000 claims description 3
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 claims description 3
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 3
- 241000194031 Enterococcus faecium Species 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000589989 Helicobacter Species 0.000 claims description 3
- 241000186713 Lactobacillus amylovorus Species 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 3
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 3
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 3
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 3
- 241001468191 Lactobacillus kefiri Species 0.000 claims description 3
- 241001134654 Lactobacillus leichmannii Species 0.000 claims description 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 108010063045 Lactoferrin Proteins 0.000 claims description 3
- 241000191998 Pediococcus acidilactici Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 3
- 229920002770 condensed tannin Polymers 0.000 claims description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 3
- 229940078795 lactoferrin Drugs 0.000 claims description 3
- 235000021242 lactoferrin Nutrition 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 3
- 241001135228 Bacteroides ovatus Species 0.000 claims description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- 241000589968 Borrelia Species 0.000 claims description 2
- 241000589562 Brucella Species 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims description 2
- 241000589601 Francisella Species 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 241000606790 Haemophilus Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 241000589902 Leptospira Species 0.000 claims description 2
- 241000186781 Listeria Species 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 241000606210 Parabacteroides distasonis Species 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000606701 Rickettsia Species 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000589886 Treponema Species 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
- 229960000511 lactulose Drugs 0.000 claims description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 43
- 230000001580 bacterial effect Effects 0.000 abstract description 26
- 235000015097 nutrients Nutrition 0.000 abstract description 22
- 230000003247 decreasing effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 18
- 239000000463 material Substances 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 235000010419 agar Nutrition 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- -1 for example Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 241000186012 Bifidobacterium breve Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940009291 bifidobacterium longum Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000009604 anaerobic growth Effects 0.000 description 4
- 239000001986 bile esculin agar Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 244000005706 microflora Species 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000006916 nutrient agar Substances 0.000 description 3
- 229940068917 polyethylene glycols Drugs 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000606126 Bacteroidaceae Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000644323 Escherichia coli C Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100032241 Lactotransferrin Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 210000004767 rumen Anatomy 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606219 Bacteroides uniformis Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001135265 Cronobacter sakazakii Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010058780 Meningitis neonatal Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000702202 Siphoviridae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Definitions
- compositions that comprise one or more types of bacteriophage and methods of using such bacteriophages as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacterial populations and releasing nutrients into the environment for good bacteria in the digestive system of an individual.
- Microflora populations containing disproportionate concentrations of undesirable organisms can be treated with antibiotics or cleansing regimes to eliminate most of the organisms in the gut, both desirable and undesirable, followed by probiotic supplement to reestablish microflora balance.
- High doses of probiotics, consumed in the form of fermented foods containing the active probiotic organism or as nutritional supplements containing a specific minimum colony count of the probiotic are somewhat effective in controlling undesirable organisms.
- large doses of the probiotic must be taken regularly to establish and to maintain colonization and to overcome the adverse environment created by undesirable organisms (Handbook of Prebiotics and Probiotics Ingredients, CRC Press, Boca Raton, Fla. 2009).
- prebiotics which are usually non-digestible carbohydrates can be used. These carbohydrate are selected for their ability to feed the probiotic organism preferentially and/or inhibit the growth or the undesirable organism. Id.
- Another mechanism which has been described for prebiotic function is inhibition of adhesion by undesirable microorganism to the intestinal wall (Quintero, M. I., “Adherence Inhibition of Cronobacter Sakazakii and Other Pathogens By Prebiotic Oligosaccharides, Plant Extracts, and Other Naturally Derived Molecules,” Dissertations & Theses in Food Science and Technology, University of Kansas, Lincoln, Apr. 22, 2011).
- adverse organisms are able to adhere and establish colonization, they modify the local environment to enhance its survival and to inhibit the colonization by competing with desirable organisms.
- Certain non-fermentable carbohydrates have structures resembling those found in the surface of epithelial cells. These prebiotics bind to the undesirable bacteria preventing it from adhering to the intestinal wall and allowing the organism to pass out of the digestive tract. Of course once the organism is attached to the intestinal wall, the prebiotic may be ineffective in dislodging it.
- SCFAs short chain fatty acids
- Unwanted symptoms relating to gas production in the gut are widely reported in human prebiotic feeding studies including flatulence, bloating and diarrhea.
- Increased cell mass and unutilized prebiotic carbohydrate can produce an undesired laxative effect by stimulation of peristalsis due to the increased bowel content (Gibson, G. R., et al., “Selective Stimulation of Bifidobacteria in the Human Colon by Oligofructose and Inulin,” Gastroenter 108:975-982, 1995).
- proteins and peptides and lipids also improve the growth of probiotics by inhibiting the undesirable organisms.
- examples are lactoferrin, proanthocyanidins, and a high molecular weight component of cranberry juice.
- These materials may have several mechanisms which inhibit colonization by undesirable organisms including inhibition of adherence. (Ofek I., et al., “Anti-adhesion Therapy of Bacterial Diseases,” FEMS Immunol Med Microbiol 38:181-191, 2003.) These materials are quite expensive and require high concentrations to be effective and their specificity may be more broad spectrum antibiotic than desired.
- compositions for increasing the growth of desirable microflora accomplish this goal by administering one or more bacteriophage, which lyse specific harmful and undesirable bacteria thus decreasing specific bacterial populations and thereby adding nutrients to the environment for the desirable bacteria.
- the disclosed subject matter in one aspect, relates to compositions and methods for preparing and using such compositions.
- the disclosed subject matter relates to compositions used as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacteria populations and by releasing nutrients extracted from the harmful bacteria into the environment, thus decreasing bacterial crowding and providing nutrients from lysed unwanted bacteria for good bacteria in the digestive system of an individual.
- the prebiotics used in the disclosed compositions and methods are one or more bacteriophages, which have been discovered herein to act as prebiotics.
- FIGURE which is incorporated in and constitutes a part of this specification, illustrates several aspects described below.
- FIG. 1 is a graph showing the optical density (a measure of cell density) measured at intervals over 10 hours for various compositions disclosed herein.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. “About” can mean within 5% of the stated value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “5” is disclosed, then “about 5” is also disclosed.
- references in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition for which a part by weight is expressed.
- X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
- a weight percent (wt. %) of a component is based on the total weight of the formulation or composition in which the component is included.
- Microbial biomass makes up over 50% of colonic contents.
- These microorganisms perform a host of useful functions, such as fermenting unused energy substrates, training the immune system, preventing growth of harmful, pathogenic bacteria, regulating the development of the gut, producing vitamins for the host (such as biotin and vitamin K), and producing hormones to direct the host to store fats.
- Probiotics are live microbial food supplements that beneficially affect the host human or animal by improving its intestinal microbial balance.
- the benefits of probiotics including displacement of undesirable or pathogenic organism, resistance to colonization of undesirable organisms by competitive exclusion and stimulation of the immune system, have been documented in numerous articles and patents.
- probiotics are taken in large quantities and over extended periods of time.
- Prebiotics are food ingredients that stimulate the growth and/or activity of a probiotic in the digestive system so that the probiotic can provide the aforementioned benefits.
- prebiotics have been carbohydrates that are not digested directly by animals or humans but that can be carbohydrate sources for specific probiotic organisms and not fermented as well by undesirable organisms. The concept is that these carbohydrates preferentially feed the probiotic organisms giving them a competitive advantage over the undesirable organisms. To be effective, large repetitive doses of the prebiotics are required. It is also clear that large concentrations of other carbohydrates consumed with meals would reduce the effectiveness of these prebiotics.
- compositions that comprise one or more lytic bacteriophages and one or more probiotic organisms.
- the bacteriophage component of the disclosed compositions acts as prebiotic to stimulate the growth of desirable organisms, including the probiotic component, as well as reduce the population of specific undesirable bacteria.
- the bacteriophage has specificity for one or more of the undesirable organisms. By weakening the population of the specific undesirable bacteria, the probiotic organisms can successfully compete and establish colonization producing an environment which is suitable for them but inhospitable to undesirable bacteria.
- the specific undesirable bacteria are lysed and their cellular contents are available as nutrients for probiotic organisms.
- the bacteriophage are very specific to the organism and as such do not directly affect any other organisms in the digestive tract or any probiotic. The dose of bacteriophage is quite small with no detectable impact on the material balance of the digestive process.
- the disclosed methods can be achieved by administering a composition as disclosed herein, and that comprises one or more lytic bacteriophages and one or more probiotic organism. Further the disclosed methods can comprise the administration of a nutrition composition as herein described. Still further, disclosed herein is a method that comprises administering one or more lytic bacteriophages and then one or more probiotic organisms, or one or more probiotic organism and then one or more lytic bacteriophages.
- compositions for increasing the growth of desirable bacteria and probiotic bacteria in the digestive system of an individual are nutritional compositions to be administered orally to an individual and can also contain vitamins, minerals, and nutrients for the individual.
- the disclosed compositions comprise one or more bacteriophages. These bacteriophages behave as prebiotics by stimulating the growth of the probiotic component of the disclosed compositions.
- the bacteriophages reduce the population of specific undesirable bacteria including but not limited to bacteroides , coliforms, lysteria, helicobacter, salmonella and staphylococcus . Each bacteriophage has specificity for an undesirable bacteria.
- the disclosed compositions can comprise one or more probiotic organisms, as disclosed elsewhere herein. No gasses or extra cellular material are produced; thus, the aforementioned undesired side effects are avoided.
- the bacteriophages of the disclosed compositions are very specific to the undesirable bacteria and, as such, do not directly affect any other organisms in the digestive tract or any probiotic. The dose of bacteriophage is quite small with no detectable impact on the material balance in the digestive process. Further by using the disclosed bacteriophages as a prebiotic, the use of more traditional prebiotics such as polysaccharides can be avoided.
- Bacteriophages Lytic bacteriophages are viruses that bind to specific bacterial cell surface receptors, inject their DNA, and take over the biosynthetic machinery of the bacterium to produce daughter phages, which are released via host lysis to re-peat the process in other target bacteria (Guttman et al., Basic phage biology. In: Bacteriophages: Biology and Applications. Kutter E and Sulakvelidze A (eds). New York: CRC Press, 2004, pp. 29-66).
- Bacteriophages have been isolated from many environments, including the gastrointestinal tracts of food animals, where they are natural members of the microbial ecosystem (Orpin et al., The occurrence of bacteriophages in the rumen and their influence on rumen bacterial population, Experientia 30:1018-1020, 1974; Klieve et al., Morphological diversity of ruminal bacteriophages from sheep and cattle, Appl Environ Microbiol 54(6):1637-1641, 1988).
- compositions comprise one or more lytic bacteriophages specifically targeted to assist probiotic organism in overcoming populations of harmful bacteria including but not limited to Bacteroides, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia and Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Vibrio and Yersinia.
- the disclosed compositions comprise a lytic bacteriophage that is a member of the Bacteroidaceae family.
- the bacteriophage is specific to Bacteroides fragilis .
- the B. fragilis group includes B. fragilis (causes the most clinical infections), Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron , and Bacteroides vulgatus . These bacteria are resistant to penicillins, mostly through the production of beta-lactamase. They are part of the normal GI florae (Brook, I., “Indigenous Microbial Flora of Humans,” In: Surgical Infectious Diseases.
- the Bacteroidaceae bacteriophages are part of the Siphoviridae family of double-stranded DNA viruses infecting only bacteria.
- the virons are nonenveloped and have a long filamentous non-contractile tail and an isometric capsid (morphotype B1).
- the filamentous cross banded tail can reach to 570 nm. It has a width of ⁇ 8 nm and is non contractile. It has short terminal and subterminal fibers.
- the genome is double stranded and linear. It is typically ⁇ 50 kilobases in length and contains ⁇ 70 genes.
- the guanine+cytosine content is ⁇ 52%.
- the disclosed compositions comprise a lytic bacteriophage that is specific to certain strains of Escherichia coli ( E. coli ).
- E. coli is a Gram-negative, rod-shaped bacterium that is commonly found in the lower intestine of warm-blooded organisms makes up about 0.1% of gut flora (Eckburg et al., Diversity of the Human Intestinal Microbial Flora, Science. 14(308):1635-1638, 2005). Most E. coli strains are harmless, but some serotypes can cause serious food poisoning in humans.
- Virulent strains of E. coli can cause gastroenteritis, urinary tract infections, and neonatal meningitis. In rare cases, virulent strains are also responsible for hemolytic-uremic syndrome, peritonitis, mastitis, septicemia and Gram-negative pneumonia.
- a bacteriophage is used, which is not the same component as a lytic protein isolated from a bacteriophage.
- the probiotic component of the disclosed compositions comprises live microorganisms that beneficially affect the host individual by displacement of undesirable or pathogenic bacteria and by creating an environment that resists colonization of the undesirable bacteria. When colonization of undesirable bacteria is present, probiotic organisms must compete with the established colonies. The combination of a beneficial bacteria with the disclosed bacteriophages can produce a symbiotic mixture.
- compositions comprise a probiotic organism that is a Lactobacillus species, such as L. acidophilus, L. amylovorus, L. brevis, L. casei, L. casei subsp. rhamnosus ( Lactobacillus GG), L. caucasicus, L. crispatus, L. delbrueckii subsp. bulgaricus ( L. bulgaricus ), L. fermentum ( L. fermenti ), L. gasseri, L. helveticus, L. johnsonii, L. lactis, L. leichmannii, L. paracasei, L. plantarum, L. reuteri , and L. rhamnosus .
- Lactobacillus species such as L. acidophilus, L. amylovorus, L. brevis, L. casei, L. casei subsp. rhamnosus ( Lactobacillus GG), L. caucasicus, L. crisp
- the disclosed compositions comprise a probiotic organism that is a Biifidobacterium species, such as B. adolescentis, B. bifidum, B. breve, B. infantis, B. lactis ( B. animalis ), B. licheniformis , and B. longum .
- the disclosed compositions comprise a probiotic organism that is a lactic acid bacteria such as Enterococcus faecium, Lactococcus lactis, Leuconstoc mesenteroides, Pediococcus acidilactici, Streptococcus thermophilus ).
- the disclosed compositions comprise a probiotic organism that is a nonlactic acid bacteria such as Bacillus subtilis, Saccharomyces boulardii , and Saccharomyces cerevisiae.
- the disclosed compositions can comprise other types of prebiotics.
- the disclosed compositions can comprise inulin, fructooligosaccharides, galactooligiosaccharides, xylooligosaccharides, polydextrose, lactulose, tagatose, isomaltooligosaccarides, soybean oligosaccharides, lactoferrin, and proanthocyanins.
- compositions can also include nutritional supplements, such as vitamins, minerals, trace elements, polyunsaturated fatty acids, antioxidants, amino acids, and the like.
- compositions disclosed herein include a bacteriophage that is specific to Bacteroides fragilis and/or E. coli and a probiotic selected from the group consisting of Lactobacillus (L.) acidophilus, L. amylovorus, L. brevis, L. casei, L. casei subsp. rhamnosus ( Lactobacillus GG), L. caucasicus, L. crispatus, L. delbrueckii subsp. bulgaricus ( L. bulgaricus ), L. fermentum ( L. fermenti ), L. gasseri, L. helveticus, L. johnsonii, L. lactis, L. leichmannii, L.
- a probiotic selected from the group consisting of Lactobacillus (L.) acidophilus, L. amylovorus, L. brevis, L. casei, L. casei subsp. rhamnosus ( Lactobacillus GG), L
- the disclosed compositions can comprise a bacteriophage that is specific to Bacteroides fragilis and/or E. coli and a probiotic selected from the group consisting of Bifidobacterium (B.) adolescentis, B. bifidum, B. breve, B. infantis, B. lactis ( B. animalis ), B. licheniformis , and B. longum .
- B. Bifidobacterium
- a probiotic selected from the group consisting of Bifidobacterium (B.) adolescentis, B. bifidum, B. breve, B. infantis, B. lactis ( B. animalis ), B. licheniformis , and B. longum .
- the disclosed compositions can comprise a bacteriophage that is specific to Bacteroides fragilis and/or E.
- compositions can comprise a bacteriophage that is specific to Bacteroides fragilis and/or E. coli and a probiotic selected from the group consisting of Bacillus subtilis, Escherichia coli strain nissle, Saccharomyces boulardii , and Saccharomyces cerevisiae.
- the compositions disclosed herein can be provided in a nutritional composition.
- the nutritional composition can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, pills, capsules, powders, liquids, or suspensions, preferably in unit dosage form suitable for single administration of a precise dosage.
- the compositions will include an effective amount of the compositions described herein optionally in combination with a biologically acceptable carrier and, in addition, can include other flavorings, thickeners, chelating agents, binders, carriers, or diluents.
- biologically acceptable is meant a material that is not biologically or otherwise undesirable, which can be administered to an individual along with the selected compositions without causing unacceptable biological effects or interacting in a deleterious manner with the other components of the nutritional composition in which it is contained.
- the term carrier encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in nutritional formulations.
- a carrier for use in a composition will depend upon the intended route of administration for the composition.
- the preparation of nutritional acceptable carriers and formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 21st Edition, ed. University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005.
- biologically acceptable carriers include buffers such as phosphate buffers, citrate buffer, and buffers with other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM (ICI, Inc.; Bridgewater, N.J.), polyethylene glycol (PEG), and PLURONICSTM (BASF; Florham Park, N.J.).
- buffers such as phosphate buffers, citrate buffer, and buffers with
- aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and animal oils (fish oil).
- a coating such as lecithin
- surfactants for example, by the use of surfactants, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- compositions can also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
- adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
- Isotonic agents for example, sugars, sodium chloride, and the like can also be included.
- Solid dosage forms for oral administration of the compositions described herein include capsules, tablets, pills, powders, and granules.
- the compositions described herein is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
- fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid
- binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia
- humectants as for example, glycerol
- disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate
- solution retarders as for example, paraffin
- absorption accelerators as for example, quaternary
- compositions of a similar type can also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
- Solid dosage forms such as tablets, dragées, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art. They can contain opacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration of the compositions described herein include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms can contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- composition can also include additional agents, such as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.
- additional agents such as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.
- Suspensions in addition to the active compounds, can contain additional agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
- additional agents as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
- compositions described herein to an individual can be carried out using effective amounts of the compositions described herein for periods of time effective to treat a disease or infection.
- An individual can include both mammals and non-mammals. Mammals include, for example, humans; nonhuman primates, e.g. apes and monkeys; cattle; horses; sheep; rats; mice; pigs; and goats. Non-mammals include, for example, fish and birds. In a preferred embodiment, the individual is a human.
- compositions described herein can be determined by one of ordinary skill in the art and includes exemplary dosage amounts for a mammal of from about 0.5 to about 200 mg/kg of body weight of active compound per day, which can be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day.
- the dosage amount can be from about 0.5 to about 150 mg/kg of body weight of active compound per day, about 0.5 to 100 mg/kg of body weight of active compound per day, about 0.5 to about 75 mg/kg of body weight of active compound per day, about 0.5 to about 50 mg/kg of body weight of active compound per day, about 0.5 to about 25 mg/kg of body weight of active compound per day, about 1 to about 20 mg/kg of body weight of active compound per day, about 1 to about 10 mg/kg of body weight of active compound per day, about 20 mg/kg of body weight of active compound per day, about 10 mg/kg of body weight of active compound per day, or about 5 mg/kg of body weight of active compound per day.
- the expression effective amount when used to describe an amount of compound in a method, refers to the amount of a compound that achieves the desired pharmacological effect or other effect, for example an amount that results in bacterial inhibition or growth.
- the bacteriophage component of the disclosed compositions can be administered in an effective amount of from 1 colony forming unit (CFU)/mL to 1 ⁇ 10 13 plaque forming unit (PFU)/mL.
- 1 PFU/mL is approximately 1 phage/mL or 1 phage/g.
- the bacteriophage component of the disclosed compositions can be administered in amounts of from about 1 ⁇ 10 2 to about 1 ⁇ 10 13 , from about 1 ⁇ 10 4 to about 1 ⁇ 10 11 , from about 1 ⁇ 10 6 to about 1 ⁇ 10 10 , from about 1 ⁇ 10 3 to about 1 ⁇ 10 9 , from about 1 ⁇ 10 5 to about 1 ⁇ 10 7 , or from about 1 ⁇ 10 7 to about 1 ⁇ 10 11 PFU/mL or PFU/g.
- the bacteriophage can be administered in amounts of from about 1 ⁇ 10 4 to about 1 ⁇ 10 6 PFU/mL or PFU/g.
- the bacteriophage component can be administered in amounts of at least about 1 ⁇ 10 1 , 1 ⁇ 10 2 , 1 ⁇ 10 3 , 1 ⁇ 10 4 , 1 ⁇ 10 5 , 1 ⁇ 10 6 , 1 ⁇ 10 7 , 1 ⁇ 10 8 , 1 ⁇ 10 9 , 1 ⁇ 10 10 , 1 ⁇ 10 11 , 1 ⁇ 10 12 , or 1 ⁇ 10 13 PFU/mL or PFU/g.
- the specific dose level and frequency of dosage for any particular subject can be varied and will depend upon a variety of factors, including the activity of the specific composition employed, the metabolic stability and length of action of that composition, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, active combination, and severity of the particular condition.
- the bacteria selected for testing included three species of Bacteroides , namely strains of fragilis, uniformis and thetaiotaomicron and two species of E. coli , namely strains of E. coli B and C and five strains of probiotics: Bacillus subtilis, Lactobacillus paracasei, Lactobacillus lactis, Bifidobacterium breve and Bifidobacterium longum.
- Bacteroides fragilis Bacteroides uniformis, Bacteroides thetaiotaomicron and four strains of probiotics; Lactobacillus paracasei, Lactobacillus lactis, Bifidobacterium breve and Bifidobacterium longum (all Bacteroides strains purchased from ATCC) were tested in vitro. Frozen permanents of each bacterial strain were streaked for single colonies using Bile Esculin agar or nutrient agar warmed prior to use. For fresh inoculants, single bacterial cells were re-streaked on a Bile Esculin agar.
- the bacteriophage was propagated from bacteroides fragilis after 16-20 hours of bacterial growth, 16000 rpm cell clearing spin for 30 minutes and collection of the supernatant. Bacteriophage were concentrated using an Amicon Ultra-15.50 kDa cutoff concentrator, titers were determined by counting plaques from serial dilutions using the bacterial host strain. The Bacteroides fragilis bacteriophage (FBP) Cocktail was diluted to 1 ⁇ 10 6 PFU/mL.
- FBP Bacteroides fragilis bacteriophage
- Bacterial cells of several fresh colonies were incubated in 50 mLs of nutrient broth (1% glucose) until the culture reached an optical density of 0.2.
- 0.2 cultures were divided into flasks and purged with a 3-5 second shot of nitrogen, bacteriophage were quickly added at a multiplicity of infection (MOI) of 1 to one set and broth to the other for a control to each flask, sealed and put back on the shaker. Anaerobic samples were opened once, tested and discarded. The optical density was measured at intervals over 10 hours. See FIG. 1 .
- a prebiotic bacteriophage was chosen for its ability to quickly and efficiently lyse Bacteroides fragilis exclusively, providing good bacteria nutrients while maintaining a healthy natural gut flora. Frozen permanents of each bacterial strain were streaked for single colonies using Bile Esculin agar or nutrient agar warmed prior to use. For fresh inoculants, single bacterial cells were re-streaked on a Bile Esculin agar. The bacteriophage was propagated from Bacteroides fragilis after 16-20 hours of bacterial growth, 16000 rpm cell clearing spin for 30 minutes and collection of the supernatant.
- Bacteriophage were concentrated using an Amicon Ultra-15.50 kDa cutoff concentrator, titers were determined by counting plaques from serial dilutions using the bacterial host strain.
- the Bacteroides fragilis bacteriophage (FBP) Cocktail was diluted to 1 ⁇ 10 6 PFU/mL.
- Bacterial cells of several fresh colonies were incubated in 50 mLs of nutrient broth (1% glucose) until the culture reached an optical density of 0.2.
- 0.2 cultures were divided into flasks and purged with a 3-5 second shot of nitrogen, bacteriophage were quickly added at a multiplicity of infection (MOI) of 1 to one set and broth to the other for a control to each flask, sealed and put back on the shaker.
- Anaerobic samples were opened once, tested and discarded.
- Probiotic alone, with bacteroides , with bacteroides and FBP cocktail together and with FBP cocktail were mixed and allowed to grow for indicated time period in a shaker bath at 37° C. and pH 6.8.
- Bacterial cells of several fresh colonies were incubated in 50 mLs of nutrient broth (1% glucose) until the culture reached an optical density of 0.2. The bacteria was spun down and re-suspended in minimal media with 1% glucose, 1% inulin or 1% Isomalta-oligosaccharide as the sole carbon source. For anaerobic growth, 0.2 cultures were divided into flasks and purged with a 3-5 second shot of nitrogen, bacteriophage were quickly added at a multiplicity of infection (MOI) of 1 to one set and broth to the other for a control to each flask, sealed and put back on the shaker. Anaerobic samples were opened once, tested and discarded.
- MOI multiplicity of infection
- Probiotic alone, with bacteroides , with bacteroides and FBP cocktail together and with FBP cocktail were mixed and allowed to grow for indicated time period in a shaker bath at 37° C. and pH 6.8.
- One milliliter samples were taken and diluted several times in Hardy Diagnostic phosphate buffer and plated on selected media for each type of probiotic and for bacteroides on bacteroides bile esculin plates (PML microbiologicals) and the selected media alone as a control. Bacteroides that grew on the selected media for the probiotic was subtracted out from the total plate count of the mixture.
- MRS agar (Neogen) plates were used for quantification of Lactobacillus
- Bifidobacterium agar Hardy Diagnostics
- Experiments were done in triplicate, multiple dilutions were done and 5 or more plates were averaged to determine bacterial counts. Test counts were subtracted out from control plates for final sample counts. See Table 2.
- E. coli B Five Enterotoxigenic Escherichia coli , or ETEC, that produces heat stable toxin (ST), five ETEC E. coli strains that produce heat labile (LT), five that produce both ST and LT toxins and E. coli O157:H7.
- ETEC Enterotoxigenic Escherichia coli
- ST heat stable toxin
- LT heat labile
- the bacteriophage were propagated from non-pathogenic E. coli B, C or K12 (all strains were a gift from Texas A&M University) after 12-16 hours of bacterial growth, 16000 rpm cell clearing spin for 30 minutes and collection of the supernatant. Bacteriophage were concentrated using an Amicon Ultra-15.50 kDa cutoff concentrator, titers were determined by counting plaques from serial dilutions using the bacterial host strain. The E. coli bacteriophage Cocktail (EBP) were diluted to 1 ⁇ 10 6 PFU/mL and mixed at a 1:1:1:1 ratio.
- EBP E. coli bacteriophage Cocktail
- Bacterial cells of several fresh colonies were incubated in 50 mLs of nutrient broth (1% glucose) until the culture reached an optical density of 0.2.
- each bacteria was grown to an O.D. of 0.2, halved and added together.
- Bacteriophages were quickly added at a multiplicity of infection (MOI) of 1 to one set and broth to the other for a control.
- MOI multiplicity of infection
- For anaerobic growth 0.2 cultures were divided into 9 flasks and purged with a 5 second shot of nitrogen, bacteriophage (MOI 1) and broth were divided up and added to each flask, sealed and put back on the shaker. Anaerobic samples were opened once, tested and discarded. Probiotic alone, probiotic with E.
- probiotic with both E. coli and EBP together and probiotic with only EBP were mixed and allowed to grow for 1 hour in a shaker bath at 37° C. and pH 6.8.
- One milliliter samples were taken and diluted several times in Hardy Diagnostic phosphate buffer and plated on selected media for each type of probiotic and for E. coli on 3M E. coli plates and the selected media alone as a control. E. coli that grew on the selected media for the probiotic was subtracted out from the total plate count of the mixture.
- Nutrient agar (Hardy Diagnostics) plates were used for quantification of Bacillus subtilis
- MRS agar (Neogen) plates were used for quantification of Lactobacillus paracasei and Lactobacillus lactis
- Bifidobacterium agar (Hardy Diagnostics) were used for the quantification of Bifidobacterium breve and Bifidobacterium longum . Experiments were done in triplicate, multiple dilutions were done and 5 or more plates were averaged to determine bacterial counts.
- Bacillus subtilis was evaluated as described above both aerobically and anaerobically. Under aerobic conditions, E. coli reduced the probiotic by almost 2 logs. With EPB added the E. coli was reduced by 10 logs while allowing the probiotic to increase 2 logs. Under anaerobic E. coli reduced the probiotic by 1 log. With EPB added E. coli was reduced by 1 log while allowing the probiotic to increase almost 2 logs (Table 3).
- Lactobacillus paracasei was evaluated as described above both aerobically and anaerobically. Under aerobic conditions, E. coli reduced the probiotic by almost 3 logs. With EPB added the E. coli was reduced by 7 logs while allowing the probiotic to increase 1 log. Under anaerobic E. coli reduced the probiotic by over 1 log. With EPB added E. coli was reduced by over 2 log while allowing the probiotic to increase almost 1 log (Table 4).
- Lactobacillus lactis was evaluated as described above anaerobically. E. coli reduced the probiotic by almost 2 logs. In presence of the EPB the E. coli was reduced by 3 logs while allowing the probiotic to increase 1 log (Table 5).
- E. coli reduced the probiotic by almost 2 logs. In presence of the EPB the E. coli was reduced by 3 log while allowing the probiotic to increase 1 log (Table 6).
- Bifidobacterium Breve was evaluated as described above anaerobically. E. coli reduced the probiotic by almost 2 logs. In presence of the EPB the E. coli was reduced by 2 log while allowing the probiotic to increase 1 log (Table 7).
- the E. coli population inhibited the growth of the probiotic organism. Also in every case, the addition of EPB reduced the E. coli by more than 98% while increasing the probiotic population by more than 10 fold.
- EPB either as a symbiotic mixture or used separately but simultaneously provides a significant improvement in probiotic growth.
- compositions and methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as illustrations of a few aspects of the claims and any compositions and methods that are functionally equivalent are within the scope of this disclosure.
- Various modifications of the compositions and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims.
- other compositions and methods and combinations of various features of the compositions and methods are intended to fall within the scope of the appended claims, even if not specifically recited.
- a combination of steps, elements, components, or constituents can be explicitly mentioned herein; however, all other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- Disclosed herein are compositions that comprise one or more types of bacteriophage and methods of using such bacteriophages as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacterial populations and releasing nutrients into the environment for good bacteria in the digestive system of an individual.
- Microflora populations containing disproportionate concentrations of undesirable organisms can be treated with antibiotics or cleansing regimes to eliminate most of the organisms in the gut, both desirable and undesirable, followed by probiotic supplement to reestablish microflora balance. High doses of probiotics, consumed in the form of fermented foods containing the active probiotic organism or as nutritional supplements containing a specific minimum colony count of the probiotic are somewhat effective in controlling undesirable organisms. To be effective, large doses of the probiotic must be taken regularly to establish and to maintain colonization and to overcome the adverse environment created by undesirable organisms (Handbook of Prebiotics and Probiotics Ingredients, CRC Press, Boca Raton, Fla. 2009).
- To assist in establishing probiotic colonization in the presence of large established populations of undesirable organisms, prebiotics, which are usually non-digestible carbohydrates can be used. These carbohydrate are selected for their ability to feed the probiotic organism preferentially and/or inhibit the growth or the undesirable organism. Id.
- Another mechanism which has been described for prebiotic function is inhibition of adhesion by undesirable microorganism to the intestinal wall (Quintero, M. I., “Adherence Inhibition of Cronobacter Sakazakii and Other Pathogens By Prebiotic Oligosaccharides, Plant Extracts, and Other Naturally Derived Molecules,” Dissertations & Theses in Food Science and Technology, University of Nebraska, Lincoln, Apr. 22, 2011). When adverse organisms are able to adhere and establish colonization, they modify the local environment to enhance its survival and to inhibit the colonization by competing with desirable organisms. Certain non-fermentable carbohydrates have structures resembling those found in the surface of epithelial cells. These prebiotics bind to the undesirable bacteria preventing it from adhering to the intestinal wall and allowing the organism to pass out of the digestive tract. Of course once the organism is attached to the intestinal wall, the prebiotic may be ineffective in dislodging it.
- The major products of probiotic metabolism are short chain fatty acids (SCFAs), the gases hydrogen and carbon dioxide, and bacterial cell mass. Unwanted symptoms relating to gas production in the gut are widely reported in human prebiotic feeding studies including flatulence, bloating and diarrhea. Increased cell mass and unutilized prebiotic carbohydrate can produce an undesired laxative effect by stimulation of peristalsis due to the increased bowel content (Gibson, G. R., et al., “Selective Stimulation of Bifidobacteria in the Human Colon by Oligofructose and Inulin,” Gastroenter 108:975-982, 1995).
- In addition to polysaccharides, certain proteins and peptides and lipids also improve the growth of probiotics by inhibiting the undesirable organisms. Examples are lactoferrin, proanthocyanidins, and a high molecular weight component of cranberry juice. These materials may have several mechanisms which inhibit colonization by undesirable organisms including inhibition of adherence. (Ofek I., et al., “Anti-adhesion Therapy of Bacterial Diseases,” FEMS Immunol Med Microbiol 38:181-191, 2003.) These materials are quite expensive and require high concentrations to be effective and their specificity may be more broad spectrum antibiotic than desired.
- What are needed are new compositions for increasing the growth of desirable microflora. The methods and compositions disclosed herein accomplish this goal by administering one or more bacteriophage, which lyse specific harmful and undesirable bacteria thus decreasing specific bacterial populations and thereby adding nutrients to the environment for the desirable bacteria.
- In accordance with the purposes of the disclosed materials, compounds, compositions, articles, and methods, as embodied and broadly described herein, the disclosed subject matter, in one aspect, relates to compositions and methods for preparing and using such compositions. In a further aspect, the disclosed subject matter relates to compositions used as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacteria populations and by releasing nutrients extracted from the harmful bacteria into the environment, thus decreasing bacterial crowding and providing nutrients from lysed unwanted bacteria for good bacteria in the digestive system of an individual. The prebiotics used in the disclosed compositions and methods are one or more bacteriophages, which have been discovered herein to act as prebiotics.
- Additional advantages will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the aspects described below. The advantages described below will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
- The accompanying FIGURE, which is incorporated in and constitutes a part of this specification, illustrates several aspects described below.
-
FIG. 1 is a graph showing the optical density (a measure of cell density) measured at intervals over 10 hours for various compositions disclosed herein. - The materials, compositions, and methods described herein can be understood more readily by reference to the following detailed description of specific aspects of the disclosed subject matter and the Examples and FIGURE included herein.
- Before the present materials, compositions, and methods are disclosed and described, it is to be understood that the aspects described below are not limited to specific synthetic methods or specific reagents, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting.
- Also, throughout this specification, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which the disclosed matter pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.
- In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings:
- Throughout the specification and claims the word “comprise” and other forms of the word, such as “comprising” and “comprises,” means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps.
- As used in the description and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a bacteriophage” includes mixtures of two or more such bacteriophages, reference to “an enzymes” includes mixtures of two or more such enzymes, reference to “the probiotic” includes mixtures of two or more such probiotics, and the like.
- “Optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. “About” can mean within 5% of the stated value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “5” is disclosed, then “about 5” is also disclosed.
- References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
- A weight percent (wt. %) of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
- Reference will now be made in detail to specific aspects of the disclosed materials, compounds, compositions, and methods, examples of which are illustrated in the accompanying Examples and FIGURE.
- Microbial biomass makes up over 50% of colonic contents. There are more than 500 different culturable species of indigenous bacteria present in the adult large intestine comprising around 1012 bacteria per gram dry weight (Moore et al., Some current concepts in intestinal bacteriology, Am. J. Clin. Nutr. 31:S33-42, 1978; Moore, et al., Intestinal flora in health and disease, Gastroenterology 86:174-193, 1984). These microorganisms perform a host of useful functions, such as fermenting unused energy substrates, training the immune system, preventing growth of harmful, pathogenic bacteria, regulating the development of the gut, producing vitamins for the host (such as biotin and vitamin K), and producing hormones to direct the host to store fats. However, in certain conditions, some species are thought to be capable of causing disease by producing infection or increasing cancer risk for the host. (Guarner et al., Gut flora in health and disease, Lancet 361(9356):512-519, 2003.)
- It is widely recognized that maintaining a proper balance of microorganisms in the intestine is essential to good health. Overpopulation of undesirable organisms modifies the intestinal environment to accommodate the undesirable species to the detriment of desirable organisms.
- Probiotics are live microbial food supplements that beneficially affect the host human or animal by improving its intestinal microbial balance. The benefits of probiotics, including displacement of undesirable or pathogenic organism, resistance to colonization of undesirable organisms by competitive exclusion and stimulation of the immune system, have been documented in numerous articles and patents. To be effective, probiotics are taken in large quantities and over extended periods of time.
- Prebiotics are food ingredients that stimulate the growth and/or activity of a probiotic in the digestive system so that the probiotic can provide the aforementioned benefits. Historically, prebiotics have been carbohydrates that are not digested directly by animals or humans but that can be carbohydrate sources for specific probiotic organisms and not fermented as well by undesirable organisms. The concept is that these carbohydrates preferentially feed the probiotic organisms giving them a competitive advantage over the undesirable organisms. To be effective, large repetitive doses of the prebiotics are required. It is also clear that large concentrations of other carbohydrates consumed with meals would reduce the effectiveness of these prebiotics.
- Disclosed herein are methods of using compositions that comprise one or more lytic bacteriophages and one or more probiotic organisms. The bacteriophage component of the disclosed compositions acts as prebiotic to stimulate the growth of desirable organisms, including the probiotic component, as well as reduce the population of specific undesirable bacteria. The bacteriophage has specificity for one or more of the undesirable organisms. By weakening the population of the specific undesirable bacteria, the probiotic organisms can successfully compete and establish colonization producing an environment which is suitable for them but inhospitable to undesirable bacteria. The specific undesirable bacteria are lysed and their cellular contents are available as nutrients for probiotic organisms. No gasses or additional cellular material are produced thus the aforementioned undesired side effects (flatulence, bloating, and diarrhea) are avoided. The bacteriophage are very specific to the organism and as such do not directly affect any other organisms in the digestive tract or any probiotic. The dose of bacteriophage is quite small with no detectable impact on the material balance of the digestive process.
- The disclosed methods can be achieved by administering a composition as disclosed herein, and that comprises one or more lytic bacteriophages and one or more probiotic organism. Further the disclosed methods can comprise the administration of a nutrition composition as herein described. Still further, disclosed herein is a method that comprises administering one or more lytic bacteriophages and then one or more probiotic organisms, or one or more probiotic organism and then one or more lytic bacteriophages.
- Disclosed herein are compositions for increasing the growth of desirable bacteria and probiotic bacteria in the digestive system of an individual. The disclosed compositions are nutritional compositions to be administered orally to an individual and can also contain vitamins, minerals, and nutrients for the individual. The disclosed compositions comprise one or more bacteriophages. These bacteriophages behave as prebiotics by stimulating the growth of the probiotic component of the disclosed compositions. The bacteriophages reduce the population of specific undesirable bacteria including but not limited to bacteroides, coliforms, lysteria, helicobacter, salmonella and staphylococcus. Each bacteriophage has specificity for an undesirable bacteria. By using the disclosed bacteriophages, specific undesirable bacteria are lysed and their cellular material is available as nutrients for the probiotic organism or endogenous. Further, by weakening the population of the specific undesirable bacteria, probiotic organisms can successfully compete and establish colonization producing an environment which is suitable for them but inhospitable to the undesirable organism. As such, the disclosed compositions can comprise one or more probiotic organisms, as disclosed elsewhere herein. No gasses or extra cellular material are produced; thus, the aforementioned undesired side effects are avoided. The bacteriophages of the disclosed compositions are very specific to the undesirable bacteria and, as such, do not directly affect any other organisms in the digestive tract or any probiotic. The dose of bacteriophage is quite small with no detectable impact on the material balance in the digestive process. Further by using the disclosed bacteriophages as a prebiotic, the use of more traditional prebiotics such as polysaccharides can be avoided.
- Bacteriophages Lytic bacteriophages are viruses that bind to specific bacterial cell surface receptors, inject their DNA, and take over the biosynthetic machinery of the bacterium to produce daughter phages, which are released via host lysis to re-peat the process in other target bacteria (Guttman et al., Basic phage biology. In: Bacteriophages: Biology and Applications. Kutter E and Sulakvelidze A (eds). New York: CRC Press, 2004, pp. 29-66). Bacteriophages have been isolated from many environments, including the gastrointestinal tracts of food animals, where they are natural members of the microbial ecosystem (Orpin et al., The occurrence of bacteriophages in the rumen and their influence on rumen bacterial population, Experientia 30:1018-1020, 1974; Klieve et al., Morphological diversity of ruminal bacteriophages from sheep and cattle, Appl Environ Microbiol 54(6):1637-1641, 1988). This disclosed compositions comprise one or more lytic bacteriophages specifically targeted to assist probiotic organism in overcoming populations of harmful bacteria including but not limited to Bacteroides, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia and Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Vibrio and Yersinia.
- In specific examples, the disclosed compositions comprise a lytic bacteriophage that is a member of the Bacteroidaceae family. In a preferred example, the bacteriophage is specific to Bacteroides fragilis. The B. fragilis group includes B. fragilis (causes the most clinical infections), Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, and Bacteroides vulgatus. These bacteria are resistant to penicillins, mostly through the production of beta-lactamase. They are part of the normal GI florae (Brook, I., “Indigenous Microbial Flora of Humans,” In: Surgical Infectious Diseases. 3rd Rd. Norwalk, Conn.: Appleton & Lange, 1995:37.) representing 30-50% of the fecal matter. They are responsible for 80% of anaerobic intra-abdominal infections. Enterotoxigenic B. fragilis (ETBF) is also a potential cause of diarrhea. (Durmaz, B., et al., “Prevalence of Enterotoxigenic Bacteroides fragilis in Patients with Diarrhea: a Controlled Study,” Anaerobe 11(6):318-321, 2005.)
- The Bacteroidaceae bacteriophages are part of the Siphoviridae family of double-stranded DNA viruses infecting only bacteria. The virons are nonenveloped and have a long filamentous non-contractile tail and an isometric capsid (morphotype B1). The icosahedral capsid (T=7) is 57 nm in diameter. It is composed of 72 capsomers that appear hexagonal in outline. The filamentous cross banded tail can reach to 570 nm. It has a width of ˜8 nm and is non contractile. It has short terminal and subterminal fibers. The genome is double stranded and linear. It is typically ˜50 kilobases in length and contains ˜70 genes. The guanine+cytosine content is ˜52%.
- In other examples, the disclosed compositions comprise a lytic bacteriophage that is specific to certain strains of Escherichia coli (E. coli). E. coli is a Gram-negative, rod-shaped bacterium that is commonly found in the lower intestine of warm-blooded organisms makes up about 0.1% of gut flora (Eckburg et al., Diversity of the Human Intestinal Microbial Flora, Science. 14(308):1635-1638, 2005). Most E. coli strains are harmless, but some serotypes can cause serious food poisoning in humans. Virulent strains of E. coli can cause gastroenteritis, urinary tract infections, and neonatal meningitis. In rare cases, virulent strains are also responsible for hemolytic-uremic syndrome, peritonitis, mastitis, septicemia and Gram-negative pneumonia.
- Rakieten et al., Studies with bacteriophages active against mucoid strains of bacteria, J. Bacteriol. 40:529-545, 1940; Demerec et al., Bacteriophage-resistant mutants in Escherichia coli, Genetics 30:119-136, 1944. Delbrück, Bacterial viruses or bacteriophages, Biol. Rev. 21:30-40, 1946.
- In the disclosed compositions and methods, a bacteriophage is used, which is not the same component as a lytic protein isolated from a bacteriophage.
- Probiotic Organisms
- The probiotic component of the disclosed compositions comprises live microorganisms that beneficially affect the host individual by displacement of undesirable or pathogenic bacteria and by creating an environment that resists colonization of the undesirable bacteria. When colonization of undesirable bacteria is present, probiotic organisms must compete with the established colonies. The combination of a beneficial bacteria with the disclosed bacteriophages can produce a symbiotic mixture.
- In specific examples, the disclosed compositions comprise a probiotic organism that is a Lactobacillus species, such as L. acidophilus, L. amylovorus, L. brevis, L. casei, L. casei subsp. rhamnosus (Lactobacillus GG), L. caucasicus, L. crispatus, L. delbrueckii subsp. bulgaricus (L. bulgaricus), L. fermentum (L. fermenti), L. gasseri, L. helveticus, L. johnsonii, L. lactis, L. leichmannii, L. paracasei, L. plantarum, L. reuteri, and L. rhamnosus. In other examples, the disclosed compositions comprise a probiotic organism that is a Biifidobacterium species, such as B. adolescentis, B. bifidum, B. breve, B. infantis, B. lactis (B. animalis), B. licheniformis, and B. longum. In still other examples, the disclosed compositions comprise a probiotic organism that is a lactic acid bacteria such as Enterococcus faecium, Lactococcus lactis, Leuconstoc mesenteroides, Pediococcus acidilactici, Streptococcus thermophilus). In yet other examples, the disclosed compositions comprise a probiotic organism that is a nonlactic acid bacteria such as Bacillus subtilis, Saccharomyces boulardii, and Saccharomyces cerevisiae.
- Additional Components
- In further embodiments, the disclosed compositions can comprise other types of prebiotics. For example, the disclosed compositions can comprise inulin, fructooligosaccharides, galactooligiosaccharides, xylooligosaccharides, polydextrose, lactulose, tagatose, isomaltooligosaccarides, soybean oligosaccharides, lactoferrin, and proanthocyanins. Though with the use of the disclosed bacteriophages, which act themselves as prebiotics, other prebiotics are not necessary.
- The disclosed compositions can also include nutritional supplements, such as vitamins, minerals, trace elements, polyunsaturated fatty acids, antioxidants, amino acids, and the like.
- Specific Combinations
- Specific examples of suitable compositions disclosed herein include a bacteriophage that is specific to Bacteroides fragilis and/or E. coli and a probiotic selected from the group consisting of Lactobacillus (L.) acidophilus, L. amylovorus, L. brevis, L. casei, L. casei subsp. rhamnosus (Lactobacillus GG), L. caucasicus, L. crispatus, L. delbrueckii subsp. bulgaricus (L. bulgaricus), L. fermentum (L. fermenti), L. gasseri, L. helveticus, L. johnsonii, L. lactis, L. leichmannii, L. paracasei, L. plantarum, L. reuteri, and L. rhamnosus. In another specific example, the disclosed compositions can comprise a bacteriophage that is specific to Bacteroides fragilis and/or E. coli and a probiotic selected from the group consisting of Bifidobacterium (B.) adolescentis, B. bifidum, B. breve, B. infantis, B. lactis (B. animalis), B. licheniformis, and B. longum. In another specific example, the disclosed compositions can comprise a bacteriophage that is specific to Bacteroides fragilis and/or E. coli and a probiotic selected from the group consisting of Enterococcus faecium, Lactococcus lactis, Leuconstoc mesenteroides, Pediococcus acidilactici, and Streptococcus thermophilus. In another specific example, the disclosed compositions can comprise a bacteriophage that is specific to Bacteroides fragilis and/or E. coli and a probiotic selected from the group consisting of Bacillus subtilis, Escherichia coli strain nissle, Saccharomyces boulardii, and Saccharomyces cerevisiae.
- As described, the compositions disclosed herein can be provided in a nutritional composition. Depending on the intended mode of administration, the nutritional composition can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, pills, capsules, powders, liquids, or suspensions, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include an effective amount of the compositions described herein optionally in combination with a biologically acceptable carrier and, in addition, can include other flavorings, thickeners, chelating agents, binders, carriers, or diluents. By “biologically acceptable” is meant a material that is not biologically or otherwise undesirable, which can be administered to an individual along with the selected compositions without causing unacceptable biological effects or interacting in a deleterious manner with the other components of the nutritional composition in which it is contained.
- As used herein, the term carrier encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in nutritional formulations. The choice of a carrier for use in a composition will depend upon the intended route of administration for the composition. The preparation of nutritional acceptable carriers and formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 21st Edition, ed. University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005. Examples of biologically acceptable carriers include buffers such as phosphate buffers, citrate buffer, and buffers with other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™ (ICI, Inc.; Bridgewater, N.J.), polyethylene glycol (PEG), and PLURONICS™ (BASF; Florham Park, N.J.). Further examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and animal oils (fish oil). Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- These compositions can also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Isotonic agents, for example, sugars, sodium chloride, and the like can also be included.
- Solid dosage forms for oral administration of the compositions described herein include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compositions described herein is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) solution retarders, as for example, paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents.
- Solid compositions of a similar type can also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
- Solid dosage forms such as tablets, dragées, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art. They can contain opacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration of the compositions described herein include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms can contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- Besides such inert diluents, the composition can also include additional agents, such as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.
- Suspensions, in addition to the active compounds, can contain additional agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
- Administration of the compositions described herein to an individual can be carried out using effective amounts of the compositions described herein for periods of time effective to treat a disease or infection. An individual can include both mammals and non-mammals. Mammals include, for example, humans; nonhuman primates, e.g. apes and monkeys; cattle; horses; sheep; rats; mice; pigs; and goats. Non-mammals include, for example, fish and birds. In a preferred embodiment, the individual is a human.
- The effective amount of the compositions described herein can be determined by one of ordinary skill in the art and includes exemplary dosage amounts for a mammal of from about 0.5 to about 200 mg/kg of body weight of active compound per day, which can be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. Alternatively, the dosage amount can be from about 0.5 to about 150 mg/kg of body weight of active compound per day, about 0.5 to 100 mg/kg of body weight of active compound per day, about 0.5 to about 75 mg/kg of body weight of active compound per day, about 0.5 to about 50 mg/kg of body weight of active compound per day, about 0.5 to about 25 mg/kg of body weight of active compound per day, about 1 to about 20 mg/kg of body weight of active compound per day, about 1 to about 10 mg/kg of body weight of active compound per day, about 20 mg/kg of body weight of active compound per day, about 10 mg/kg of body weight of active compound per day, or about 5 mg/kg of body weight of active compound per day. The expression effective amount, when used to describe an amount of compound in a method, refers to the amount of a compound that achieves the desired pharmacological effect or other effect, for example an amount that results in bacterial inhibition or growth.
- For the bacteriophage component of the disclosed compositions, they can be administered in an effective amount of from 1 colony forming unit (CFU)/mL to 1×1013 plaque forming unit (PFU)/mL. 1 PFU/mL is approximately 1 phage/mL or 1 phage/g. In certain examples the bacteriophage component of the disclosed compositions can be administered in amounts of from about 1×102 to about 1×1013, from about 1×104 to about 1×1011, from about 1×106 to about 1×1010, from about 1×103 to about 1×109, from about 1×105 to about 1×107, or from about 1×107 to about 1×1011 PFU/mL or PFU/g. In further examples the bacteriophage can be administered in amounts of from about 1×104 to about 1×106 PFU/mL or PFU/g. In still further examples, the bacteriophage component can be administered in amounts of at least about 1×101, 1×102, 1×103, 1×104, 1×105, 1×106, 1×107, 1×108, 1×109, 1×1010, 1×1011, 1×1012, or 1×1013 PFU/mL or PFU/g.
- Those of skill in the art will understand that the specific dose level and frequency of dosage for any particular subject can be varied and will depend upon a variety of factors, including the activity of the specific composition employed, the metabolic stability and length of action of that composition, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, active combination, and severity of the particular condition.
- The examples below are intended to further illustrate certain aspects of the methods and compounds described herein, and are not intended to limit the scope of the claims.
- The following examples are set forth below to illustrate the methods and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations that are apparent to one skilled in the art.
- Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. or is at ambient temperature, and pressure is at or near atmospheric. There are numerous variations and combinations of reaction conditions, e.g., component concentrations, temperatures, pressures and other reaction ranges and conditions that can be used to optimize the product purity and yield obtained from the disclosed process. Only reasonable and routine experimentation will be required to optimize such process conditions.
- In vitro studies to determine the ability of bacteriophage to allow specific changes, both in the composition and/or activity in gastrointestinal microflora, were done under physiological conditions of the small intestine (37° C. and pH 6.8). The bacteria selected for testing included three species of Bacteroides, namely strains of fragilis, uniformis and thetaiotaomicron and two species of E. coli, namely strains of E. coli B and C and five strains of probiotics: Bacillus subtilis, Lactobacillus paracasei, Lactobacillus lactis, Bifidobacterium breve and Bifidobacterium longum.
- Bacteroides fragilis, Bacteroides uniformis, Bacteroides thetaiotaomicron and four strains of probiotics; Lactobacillus paracasei, Lactobacillus lactis, Bifidobacterium breve and Bifidobacterium longum (all Bacteroides strains purchased from ATCC) were tested in vitro. Frozen permanents of each bacterial strain were streaked for single colonies using Bile Esculin agar or nutrient agar warmed prior to use. For fresh inoculants, single bacterial cells were re-streaked on a Bile Esculin agar. The bacteriophage was propagated from bacteroides fragilis after 16-20 hours of bacterial growth, 16000 rpm cell clearing spin for 30 minutes and collection of the supernatant. Bacteriophage were concentrated using an Amicon Ultra-15.50 kDa cutoff concentrator, titers were determined by counting plaques from serial dilutions using the bacterial host strain. The Bacteroides fragilis bacteriophage (FBP) Cocktail was diluted to 1×106 PFU/mL.
- Bacterial cells of several fresh colonies were incubated in 50 mLs of nutrient broth (1% glucose) until the culture reached an optical density of 0.2. For anaerobic growth, 0.2 cultures were divided into flasks and purged with a 3-5 second shot of nitrogen, bacteriophage were quickly added at a multiplicity of infection (MOI) of 1 to one set and broth to the other for a control to each flask, sealed and put back on the shaker. Anaerobic samples were opened once, tested and discarded. The optical density was measured at intervals over 10 hours. See
FIG. 1 . - The addition of the FBP to the Bacteroides fragilis culture rapidly reduced the population while the addition of FBP had no effect on any of the other organisms tested.
- Bacteroides fragilis and four strains of probiotics; Lactobacillus paracasei, Lactobacillus lactis, Bifidobacterium breve and Bifidobacterium longum (all Bacteroides strains purchased from ATCC) were tested in vitro. Bacteroides is the dominate bacteria in the human gut, while most of the time, most of the strains of Bacteroides are symbiotic, certain bacteroides strains can be pathogenic. One of the main bacteroides strains known to cause pathogenicity in humans is bacteroides fragilis, which can take over the gastrointestinal tract robbing nutrients and crowding out good bacteria. For that reason, a prebiotic bacteriophage was chosen for its ability to quickly and efficiently lyse Bacteroides fragilis exclusively, providing good bacteria nutrients while maintaining a healthy natural gut flora. Frozen permanents of each bacterial strain were streaked for single colonies using Bile Esculin agar or nutrient agar warmed prior to use. For fresh inoculants, single bacterial cells were re-streaked on a Bile Esculin agar. The bacteriophage was propagated from Bacteroides fragilis after 16-20 hours of bacterial growth, 16000 rpm cell clearing spin for 30 minutes and collection of the supernatant. Bacteriophage were concentrated using an Amicon Ultra-15.50 kDa cutoff concentrator, titers were determined by counting plaques from serial dilutions using the bacterial host strain. The Bacteroides fragilis bacteriophage (FBP) Cocktail was diluted to 1×106 PFU/mL.
- Bacterial cells of several fresh colonies were incubated in 50 mLs of nutrient broth (1% glucose) until the culture reached an optical density of 0.2. For anaerobic growth, 0.2 cultures were divided into flasks and purged with a 3-5 second shot of nitrogen, bacteriophage were quickly added at a multiplicity of infection (MOI) of 1 to one set and broth to the other for a control to each flask, sealed and put back on the shaker. Anaerobic samples were opened once, tested and discarded. Probiotic alone, with bacteroides, with bacteroides and FBP cocktail together and with FBP cocktail were mixed and allowed to grow for indicated time period in a shaker bath at 37° C. and pH 6.8. One milliliter samples were taken and diluted several times in Hardy Diagnostic phosphate buffer and plated on selected media for each type of probiotic and for bacteroides on bacteroides bile esculin plates (PML microbiologicals) and the selected media alone as a control. Bacteroides that grew on the selected media for the probiotic was subtracted out from the total plate count of the mixture. MRS agar (Neogen) plates were used for quantification of Lactobacillus strains, Bifidobacterium agar (Hardy Diagnostics) were used for the quantification of Bifidobacterium strains. Experiments were done in triplicate, multiple dilutions were done and 5 or more plates were averaged to determine bacterial counts. Test counts were subtracted out from control plates for final sample counts. See Table 1.
-
TABLE 1 Nutrient Broth CFU/mL after 5 hr Bacteroides Strains L. Paracasei Fragilis Individual (anaerobic) 1 × 103 4 × 103 L. Paracasei + Bacteroides Fragilis 2 × 102 1 × 102 L. Paracasei + Bacteroides Fragilis + 7 × 103 5 FBP Bacteroides Strains L. Lactis Fragilis Individual (anaerobic) 9 × 103 1 × 104 L. Lactis + Bacteroides Fragilis 7 × 102 3 × 103 L. Lactis + Bacteroides Fragilis + 2 × 104 0 FBP Bacteroides Strains B. Longum Fragilis Individual (anaerobic) 2 × 103 6 × 103 B. Longum + Bacteroides Fragilis 1 × 102 1 × 103 B. Longum + Bacteroides Fragilis + 7 × 103 12 FBP Bacteroides Strains B. Breve Fragilis Individual (anaerobic) 1 × 104 9 × 103 B. Breve + Bacteroides Fragilis 4 × 102 7 × 103 B. Breve + Bacteroides Fragilis + 5 × 104 6 FBP - Mixed cultures of Bacteroides fragilis and each of the probiotics reduced the growth of both the probiotic and of the Bacteroides as compared with the pure cultures. The addition of FPB cocktail essentially eliminated the Bacteroides fragilis while significantly increasing the growth of each probiotic over the controls. These results indicate that the lytic activity on the Bacteroides provides nutrients which stimulate the growth of each of the probiotics tested.
- Bacterial cells of several fresh colonies were incubated in 50 mLs of nutrient broth (1% glucose) until the culture reached an optical density of 0.2. The bacteria was spun down and re-suspended in minimal media with 1% glucose, 1% inulin or 1% Isomalta-oligosaccharide as the sole carbon source. For anaerobic growth, 0.2 cultures were divided into flasks and purged with a 3-5 second shot of nitrogen, bacteriophage were quickly added at a multiplicity of infection (MOI) of 1 to one set and broth to the other for a control to each flask, sealed and put back on the shaker. Anaerobic samples were opened once, tested and discarded. Probiotic alone, with bacteroides, with bacteroides and FBP cocktail together and with FBP cocktail were mixed and allowed to grow for indicated time period in a shaker bath at 37° C. and pH 6.8. One milliliter samples were taken and diluted several times in Hardy Diagnostic phosphate buffer and plated on selected media for each type of probiotic and for bacteroides on bacteroides bile esculin plates (PML microbiologicals) and the selected media alone as a control. Bacteroides that grew on the selected media for the probiotic was subtracted out from the total plate count of the mixture. MRS agar (Neogen) plates were used for quantification of Lactobacillus, Bifidobacterium agar (Hardy Diagnostics) were used for the quantification of Bifidobacterium. Experiments were done in triplicate, multiple dilutions were done and 5 or more plates were averaged to determine bacterial counts. Test counts were subtracted out from control plates for final sample counts. See Table 2.
-
TABLE 2 MM + Inulin CFU/mL after 48 hr Bacteroides Strain(s) L. Paracasei Fragilis Individual (anaerobic) 2730 0 L. Paracasei + Bacteroides Fragilis 2850 0 L. Paracasei + Bacteroides Fragilis + 2650 0 FBP Bacteroides Strain(s) B. Longum Fragilis Individual (anaerobic) 2590 0 B. Longum + Bacteroides Fragilis 2340 0 B. Longum + Bacteroides Fragilis + 2570 0 FBP MM + Vitafiber CFU/mL after 48 hr Bacteroides Strain(s) L. Paracasei Fragilis Individual (anaerobic) 3610 1240 L. Paracasei + Bacteroides Fragilis 2780 970 L. Paracasei + Bacteroides Fragilis + 3830 0 FBP Bacteroides Strain(s) B. Longum Fragilis Individual (anaerobic) 3980 1060 B. Longum + Bacteroides Fragilis 2790 780 B. Longum + Bacteroides Fragilis + 4120 0 FBP Nutrient + Inulin CFU/mL after 48 hr Bacteroides Strain(s) L. Paracasei Fragilis Individual (anaerobic) 1 × 106 9 × 104 L. Paracasei + Bacteroides Fragilis 9 × 103 6 × 102 L. Paracasei + Bacteroides Fragilis + 8 × 106 16 FBP Bacteroides Strain(s) B. Longum Fragilis Individual (anaerobic) 7 × 106 8 × 104 B. Longum + Bacteroides Fragilis 2 × 104 1 × 103 B. Longum + Bacteroides Fragilis + 1 × 107 23 FBP Nutrient + Vitafiber CFU/mL after 48 hr Bacteroides Strain(s) L. Paracasei Fragilis Individual (anaerobic) 3 × 106 6 × 105 L. Paracasei + Bacteroides Fragilis 4 × 104 5 × 103 L. Paracasei + Bacteroides Fragilis + 4 × 107 10 FBP Bacteroides Strain(s) B. Longum Fragilis Individual (anaerobic) 1 × 106 3 × 105 B. Longum + Bacteroides Fragilis 1 × 104 7 × 103 B. Longum + Bacteroides Fragilis + 8 × 106 8 FBP - The results indicate that the bacteriophage had no negative effect on either the Lactobacillus or Bifidobacterium. Neither inulin nor Isomalta-oligosaccharide alone were good nutrients for any of the organisms. In nutrient broth with either inulin or Isomalta-oligosaccharide added the Bacteroides and probiotics inhibit each other's growth. In nutrient broth with either inulin or Isomalta-oligosaccharide added, in the presence of the bacteriophage, the Bacteroides fragilis population is reduced by several logs while the probiotic population is increased about 3 logs and about one log over the probiotic controls. This corresponds to the previous experiment and provides further evidence that the lysed bacteroides is being used by the probiotics as nutrient.
- Four bacteriophage were chosen for their ability to quickly and efficiently lyses several strains of E. coli including E. coli B, five Enterotoxigenic Escherichia coli, or ETEC, that produces heat stable toxin (ST), five ETEC E. coli strains that produce heat labile (LT), five that produce both ST and LT toxins and E. coli O157:H7.
- The bacteriophage were propagated from non-pathogenic E. coli B, C or K12 (all strains were a gift from Texas A&M University) after 12-16 hours of bacterial growth, 16000 rpm cell clearing spin for 30 minutes and collection of the supernatant. Bacteriophage were concentrated using an Amicon Ultra-15.50 kDa cutoff concentrator, titers were determined by counting plaques from serial dilutions using the bacterial host strain. The E. coli bacteriophage Cocktail (EBP) were diluted to 1×106 PFU/mL and mixed at a 1:1:1:1 ratio.
- Bacterial cells of several fresh colonies were incubated in 50 mLs of nutrient broth (1% glucose) until the culture reached an optical density of 0.2. For competition experiments, each bacteria was grown to an O.D. of 0.2, halved and added together. Bacteriophages were quickly added at a multiplicity of infection (MOI) of 1 to one set and broth to the other for a control. For anaerobic growth, 0.2 cultures were divided into 9 flasks and purged with a 5 second shot of nitrogen, bacteriophage (MOI 1) and broth were divided up and added to each flask, sealed and put back on the shaker. Anaerobic samples were opened once, tested and discarded. Probiotic alone, probiotic with E. coli, probiotic with both E. coli and EBP together and probiotic with only EBP were mixed and allowed to grow for 1 hour in a shaker bath at 37° C. and pH 6.8. One milliliter samples were taken and diluted several times in Hardy Diagnostic phosphate buffer and plated on selected media for each type of probiotic and for E. coli on 3M E. coli plates and the selected media alone as a control. E. coli that grew on the selected media for the probiotic was subtracted out from the total plate count of the mixture. Nutrient agar (Hardy Diagnostics) plates were used for quantification of Bacillus subtilis, MRS agar (Neogen) plates were used for quantification of Lactobacillus paracasei and Lactobacillus lactis, Bifidobacterium agar (Hardy Diagnostics) were used for the quantification of Bifidobacterium breve and Bifidobacterium longum. Experiments were done in triplicate, multiple dilutions were done and 5 or more plates were averaged to determine bacterial counts.
- Bacillus subtilis was evaluated as described above both aerobically and anaerobically. Under aerobic conditions, E. coli reduced the probiotic by almost 2 logs. With EPB added the E. coli was reduced by 10 logs while allowing the probiotic to increase 2 logs. Under anaerobic E. coli reduced the probiotic by 1 log. With EPB added E. coli was reduced by 1 log while allowing the probiotic to increase almost 2 logs (Table 3).
-
TABLE 3 Log CFU Bacillus Subtilis E. coli B Individual (aerobic) 7.3 9.8 B. Subtilis + E. coli B(aerobic) 5.6 7.8 B. Subtilis + E. coli B + EBP(aerobic) 7.7 0.0 Individual (anaerobic) 3.0 4.5 B. Subtilis + E. coli B(anaerobic) 1.9 3.0 B. Subtilis + E. coli B + EBP(anaerobic) 3.6 2.0 - Lactobacillus paracasei was evaluated as described above both aerobically and anaerobically. Under aerobic conditions, E. coli reduced the probiotic by almost 3 logs. With EPB added the E. coli was reduced by 7 logs while allowing the probiotic to increase 1 log. Under anaerobic E. coli reduced the probiotic by over 1 log. With EPB added E. coli was reduced by over 2 log while allowing the probiotic to increase almost 1 log (Table 4).
-
TABLE 4 Log CFU L. Paracasei E. coli B Individual (aerobic) 5.5 9.0 L. Paracasei + E. coli B (aerobic) 2.8 7.0 L. Paracasei + E. coli B + EBP (aerobic) 4.0 0.5 Individual (anaerobic) 3.0 6.0 L. Paracasei + E. coli B (anaerobic) 1.5 5.0 L. Paracasei + E. coli B + EBP (anaerobic) 2.8 2.5 - Lactobacillus lactis was evaluated as described above anaerobically. E. coli reduced the probiotic by almost 2 logs. In presence of the EPB the E. coli was reduced by 3 logs while allowing the probiotic to increase 1 log (Table 5).
-
TABLE 5 Log CFU L. Lactis E. coli B Individual (anaerobic) 3.8 5.9 L. Lactis + E. coli B 2.0 4.0 L. Lactis + E. coli B + EBP 3.0 1.0 - Bifidobacterium longum was evaluated as described above anaerobically. E. coli reduced the probiotic by almost 2 logs. In presence of the EPB the E. coli was reduced by 3 log while allowing the probiotic to increase 1 log (Table 6).
-
TABLE 6 Log CFU B. Longum E. coli B Individual (anaerobic) 4.3 5.9 B. Longum + E. coli B 2.5 4.3 B. Longum + E. coli B + EBP 3.8 1.0 - Bifidobacterium Breve was evaluated as described above anaerobically. E. coli reduced the probiotic by almost 2 logs. In presence of the EPB the E. coli was reduced by 2 log while allowing the probiotic to increase 1 log (Table 7).
-
TABLE 7 Log CFU B. Breve E. coli B Individual (anaerobic) 4.5 5.9 B. Breve + E. coli B 2.8 4.7 B. Breve + E. coli B + EBP 4.0 2.3 - In each example, the E. coli population inhibited the growth of the probiotic organism. Also in every case, the addition of EPB reduced the E. coli by more than 98% while increasing the probiotic population by more than 10 fold.
- Clearly the use of EPB either as a symbiotic mixture or used separately but simultaneously provides a significant improvement in probiotic growth.
- The compositions and methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as illustrations of a few aspects of the claims and any compositions and methods that are functionally equivalent are within the scope of this disclosure. Various modifications of the compositions and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims. Further, while only certain representative compositions, methods, and aspects of these compositions and methods are specifically described, other compositions and methods and combinations of various features of the compositions and methods are intended to fall within the scope of the appended claims, even if not specifically recited. Thus a combination of steps, elements, components, or constituents can be explicitly mentioned herein; however, all other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/837,730 US20180161382A1 (en) | 2012-10-30 | 2017-12-11 | Prebiotic compositions comprising one or more types of bacteriophage |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261720121P | 2012-10-30 | 2012-10-30 | |
PCT/US2013/029796 WO2014070225A1 (en) | 2012-10-30 | 2013-03-08 | Prebiotic compositions comprising one or more types of bacteriophage |
US201514439866A | 2015-04-30 | 2015-04-30 | |
US15/837,730 US20180161382A1 (en) | 2012-10-30 | 2017-12-11 | Prebiotic compositions comprising one or more types of bacteriophage |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/029796 Division WO2014070225A1 (en) | 2012-10-30 | 2013-03-08 | Prebiotic compositions comprising one or more types of bacteriophage |
US14/439,866 Division US9839657B2 (en) | 2012-10-30 | 2013-03-08 | Prebiotic compositions comprising one or more types of bacteriophage |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180161382A1 true US20180161382A1 (en) | 2018-06-14 |
Family
ID=50627900
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/439,866 Active 2033-11-26 US9839657B2 (en) | 2012-10-30 | 2013-03-08 | Prebiotic compositions comprising one or more types of bacteriophage |
US15/837,730 Pending US20180161382A1 (en) | 2012-10-30 | 2017-12-11 | Prebiotic compositions comprising one or more types of bacteriophage |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/439,866 Active 2033-11-26 US9839657B2 (en) | 2012-10-30 | 2013-03-08 | Prebiotic compositions comprising one or more types of bacteriophage |
Country Status (2)
Country | Link |
---|---|
US (2) | US9839657B2 (en) |
WO (1) | WO2014070225A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021055875A1 (en) * | 2019-09-18 | 2021-03-25 | Ancilia, Inc. | Compositions and methods for microbiome modulation |
WO2023062328A1 (en) | 2021-10-15 | 2023-04-20 | Lesaffre Et Compagnie | Mixture of at least one bacteriophage and of at least one yeast and method for drying same |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US20150050245A1 (en) * | 2013-08-14 | 2015-02-19 | Tntgamble, Inc. | Methods and delivery system for beneficial additive and subtractive biological agents to promote balanced mammalian gastrointestinal flora |
KR20220151045A (en) | 2014-12-23 | 2022-11-11 | 4디 파마 리서치 리미티드 | Immune modulation |
SG10202105996WA (en) | 2014-12-23 | 2021-07-29 | 4D Pharma Res Ltd | Pirin polypeptide and immune modulation |
ITUB20150028A1 (en) * | 2015-04-22 | 2016-10-22 | Copma S C A S R L | PRODUCT FOR CLEANING, SANITIZATION AND SANITIZATION |
RS59308B1 (en) | 2015-06-15 | 2019-10-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MD3240554T2 (en) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases |
MA41060B1 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
PL3206700T3 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MA41010B1 (en) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
ME03003B (en) | 2015-11-20 | 2018-10-20 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
RS58869B1 (en) | 2016-03-04 | 2019-08-30 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
KR20220138015A (en) | 2016-04-01 | 2022-10-12 | 트러스티즈 오브 터프츠 칼리지 | Methods and compositions for preventing infection by a vibrio species |
TW201821093A (en) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | Compositions comprising bacterial strains |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
WO2018125735A1 (en) * | 2016-12-29 | 2018-07-05 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
EP3595689A4 (en) * | 2017-03-14 | 2020-12-09 | Brigham Young University | Methods and compositions for treating obesity, inflammation, or metabolic disorders with bacteriophages |
TWI787272B (en) | 2017-05-22 | 2022-12-21 | 英商4D製藥研究有限公司 | Compositions comprising bacterial strains |
JP6978514B2 (en) | 2017-05-24 | 2021-12-08 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | Composition containing bacterial strain |
JP6884889B2 (en) | 2017-06-14 | 2021-06-09 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | Compositions Containing Bacterial Strains |
KR20200015575A (en) | 2017-06-14 | 2020-02-12 | 4디 파마 리서치 리미티드 | Compositions Containing Bacterial Strains |
US11850270B2 (en) | 2017-12-04 | 2023-12-26 | The BioCollective, LLC | Probiotics and methods of use |
US10842811B2 (en) | 2018-02-28 | 2020-11-24 | The Trustees Of Columbia University In The City Of New York | Inulin for preventing antibiotic resistant infection and pathogen colonization |
US11986502B2 (en) | 2018-05-23 | 2024-05-21 | Optium, LLC | Bacteriophage compositions and kits and related methods |
CA3101242A1 (en) * | 2018-05-23 | 2019-11-28 | Brigham Young University | Bacteriophage compositions and kits and related methods |
CN111925995B (en) * | 2020-07-04 | 2022-05-17 | 菲吉乐科(南京)生物科技有限公司 | Microecological preparation prepared by coupling fermentation of bacteriophage and probiotics and preparation method |
US20220264896A1 (en) * | 2020-12-21 | 2022-08-25 | Intralytix, Inc. | Novel campylobacter bacteriophages and uses thereof |
US20220323517A1 (en) * | 2021-04-10 | 2022-10-13 | Intron Biotechnology, Inc. | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis |
US20220323518A1 (en) * | 2021-04-10 | 2022-10-13 | Intron Biotechnology, Inc. | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis |
US20220331381A1 (en) * | 2021-04-10 | 2022-10-20 | Intron Biotechnology, Inc. | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis |
CN113368221A (en) * | 2021-06-21 | 2021-09-10 | 南京北极光生物科技有限公司 | Composition, preparation method and application thereof in treating bacterial diseases |
CN113637606A (en) * | 2021-08-10 | 2021-11-12 | 南京北极光生物科技有限公司 | Microorganism combined preparation compounded by metazoan and phage, preparation method and application thereof |
CN114107129A (en) * | 2021-12-15 | 2022-03-01 | 青岛润达生物科技有限公司 | Enterococcus faecium strain and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6461608B1 (en) * | 2000-11-22 | 2002-10-08 | Nymox Pharmaceutical Corporation | Bacteriophage composition useful in treating food products to prevent bacterial contamination |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE206873T1 (en) | 1997-01-09 | 2001-11-15 | Nestle Sa | CEREAL PRODUCT CONTAINING PROBIOTICS |
DK1458856T3 (en) | 2001-12-13 | 2012-07-09 | Nestle Sa | ISOLATED SUBJECTS AND THEIR USE IN FOOD OR PETS FEED PRODUCTS |
US20050106132A1 (en) * | 2003-08-14 | 2005-05-19 | Porubcan Randolph S. | Growth promoting prebiotic for lactobacillus dietary supplements |
US8444967B2 (en) * | 2010-07-09 | 2013-05-21 | Master Supplements, Inc. | Treatment including prebiotic composition for use with probiotics |
US9492487B2 (en) | 2010-02-01 | 2016-11-15 | Matthew Ryan Garner | Microbial product containing multiple microorganisms |
-
2013
- 2013-03-08 US US14/439,866 patent/US9839657B2/en active Active
- 2013-03-08 WO PCT/US2013/029796 patent/WO2014070225A1/en active Application Filing
-
2017
- 2017-12-11 US US15/837,730 patent/US20180161382A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6461608B1 (en) * | 2000-11-22 | 2002-10-08 | Nymox Pharmaceutical Corporation | Bacteriophage composition useful in treating food products to prevent bacterial contamination |
Non-Patent Citations (1)
Title |
---|
H. Brüssow and F. Desiere. Comparative phage genomics and the evolution of Siphoviridae: insights from dairy phages. (Molecular Microbiology (2001), 39(2), 213-222. (Year: 2001) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021055875A1 (en) * | 2019-09-18 | 2021-03-25 | Ancilia, Inc. | Compositions and methods for microbiome modulation |
WO2023062328A1 (en) | 2021-10-15 | 2023-04-20 | Lesaffre Et Compagnie | Mixture of at least one bacteriophage and of at least one yeast and method for drying same |
FR3128227A1 (en) | 2021-10-15 | 2023-04-21 | Lesaffre Et Compagnie | Mixture of at least one bacteriophage and at least one yeast and method of drying them |
Also Published As
Publication number | Publication date |
---|---|
US9839657B2 (en) | 2017-12-12 |
WO2014070225A1 (en) | 2014-05-08 |
US20150297648A1 (en) | 2015-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180161382A1 (en) | Prebiotic compositions comprising one or more types of bacteriophage | |
US20240123000A1 (en) | Treatment of clostridium difficile infection | |
US11701396B2 (en) | Treatment of Clostridium difficile infection | |
He et al. | Lactobacillus johnsonii L531 reduces pathogen load and helps maintain short-chain fatty acid levels in the intestines of pigs challenged with Salmonella enterica Infantis | |
EP3639834B1 (en) | Use of microbial communities for human and animal health | |
CN113180109B (en) | Application of lactobacillus reuteri in preparation of products for preventing or treating developmental disorder diseases | |
US6613549B2 (en) | Probiotic therapy for newborns | |
Tejero-Sariñena et al. | Antipathogenic activity of probiotics against Salmonella Typhimurium and Clostridium difficile in anaerobic batch culture systems: is it due to synergies in probiotic mixtures or the specificity of single strains? | |
Gu et al. | Probiotic properties of lactic acid bacteria isolated from stool samples of longevous people in regions of Hotan, Xinjiang and Bama, Guangxi, China | |
JP2008538913A (en) | Probiotic compositions suitable for animals | |
BR112012011315B1 (en) | Formulation comprising probiotic bifidobacteria strain | |
CN112877233B (en) | Lactobacillus helveticus strain and application thereof | |
Yakabe et al. | Safety assessment of Lactobacillus brevis KB290 as a probiotic strain | |
AU2019379234A1 (en) | Strains, composition and method of use | |
US6841149B1 (en) | Probiotic mixture intended for monogastric animals to control intestinal flora populations | |
CN115666605A (en) | Compositions for improving athletic performance and methods of use thereof | |
JP5082048B2 (en) | A novel lactic acid bacterium having immunostimulatory action and / or allergy-suppressing action and gastric juice resistance | |
Lee et al. | Glycosaminoglycan degradation-inhibitory lactic acid bacteria ameliorate 2, 4, 6-trinitrobenzenesulfonic acid-induced colitis in mice | |
PL212096B1 (en) | New strains of bifidobacterium having the ability to produce glutamine | |
Murphy | In vivo assessment of potential probiotic Lactobacillus salivarius strains: evaluation of their establishment, persistence, and localisation in the murine gastrointestinal tract | |
US11850270B2 (en) | Probiotics and methods of use | |
SI24570A (en) | New strains of the genus Lactobacillus and use thereof | |
US20240082321A1 (en) | Stimulation of the growth of gut bifidobacteria | |
CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
Zhang et al. | Safety assessment of Lactobacillus salivarius REN, a probiotic strain isolated from centenarian feces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DEERLAND ENZYMES, INC., GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEATON, JOHN;ERTLE, ELIZABETH;DAWSON, HILTON GRANT;REEL/FRAME:045181/0911 Effective date: 20130117 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
AS | Assignment |
Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT, MARYL Free format text: SECURITY INTEREST;ASSIGNOR:DEERLAND PROBIOTICS & ENZYMES, INC.;REEL/FRAME:050902/0572 Effective date: 20191031 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: DEERLAND PROBIOTICS & ENZYMES, INC., ILLINOIS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:058277/0765 Effective date: 20211118 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |